Company / Operating Cash Flow
Editas Medicine, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$210.3M
FY2025
5-year range
-$210.3M / -$40.7M
FY2021-FY2025
Trend
-18.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 8 years, ranging from -$210M in FY2025 to -$9M in FY2019.
Based on SEC 10-K filings.
-$210M in FY2025.
Declined from -$164M to -$210M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 18.6% year-over-year.
- Peak operating cash flow was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -2.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$210.3M | -18.6% |
| FY2024 | -$177.3M | -8.3% |
| FY2023 | -$163.8M | +8.9% |
| FY2022 | -$179.8M | -342.2% |
| FY2021 | -$40.7M | +11.0% |
| FY2020 | -$45.7M | -385.4% |
| FY2019 | -$9.4M | +81.3% |
| FY2018 | -$50.2M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026